الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 80 |  |  |
| | | from | 80 | | |
Abstract
Cisplatin is a well-established chemotherapeutic agent utilized in the treatment of various types of solid organ cancers. Its cytotoxic effects were first identified in the 1960s, and since then, it has become widely recognized as a fundamental component in the systemic treatment of germ cell tumors.
Despite the effectiveness of cisplatin, its utilization is hindered due to multiorgan toxicity, specifically nephrotoxicity, which has been recognized for over a quarter of a century. Extensive documentation confirms its association with tubular damage, oxidative stress, apoptosis, interstitial inflammation, and fibrosis. The occurrence of nephrotoxicity can result in kidney damage or the manifestation of various clinical renal symptoms. Failure to treat cisplatin-induced AKI poses a potential threat, as it may progress into chronic kidney injury, leading to terminal renal failure and heightened mortality rates.
Recent studies suggest that the administration of antioxidants could potentially mitigate the detrimental effects of cisplatin. While vitamin D is traditionally known for its role in bone metabolism, it has been found to have various additional therapeutic applications. Vitamin D exhibits several cytoprotective properties, including anti-fibrotic, anti-oxidative, and anti-inflammatory activities, making it a promising candidate for minimizing the harmful effects of cisplatin.